Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) stock has touched a 52-week low, dropping to $0.72, as the company faces a ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5.3 million, announced the ...

Adial Pharmaceuticals has completed a pharmacokinetics study of its investigational drug AD04, aimed at treating Alcohol Use Disorder (AUD) in patients with a specific genomic biomarker.

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder. PE: Were there any specific patient demographics or ...

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company, on Wednesday announced promising results from its AD04-103 Pharmacokinetics or PK Study for AD04 ...

Adial Pharmaceuticals has updated its corporate presentation, highlighting the development of AD04, a genetically targeted precision medication for treating Alcohol Use Disorder (AUD). The ...

(RTTNews) - Adial Pharmaceuticals, Inc. (ADIL), Wednesday revealed positive results from its pharmacokinetics study of AD04 for the treatment of Alcohol Use Disorder in patients with a 5-HT3 genomic ...

On Wednesday, Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality ...

On Wednesday, Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality, no food ...